General description

A cell permeable, potent, and selective oxime PDE4D inhibitor (IC₅₀ = 0.67 µM) which displays much reduced activities toward other PDE4 isoforms. It is shown to cause a significant 40% increase in extracellular cAMP in the hippocampus of freely moving rats in vivo at 100 µM, but has no effect on Aβ levels. This compound elicits cognitive enhancement in vivo at the optimum dose of 0.003 mg/kg in both mice and rat models, and unlike rolipram, does not cause emesis-like behavior in rodents.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Bruno, O., et al. 2011. Br. J. Pharmacol.in press.Bruno, O., et al. 2009. J. Med. Chem.52, 6546.

Packaging

5 mg in Glass bottle

Packaged under inert gas

Warning

Toxicity: Standard Handling (A)